HomeBUSINESS
BUSINESS

EA Pharma Licenses Secondary Hyperparathyroidism Med AJT240 to JW Pharma
(Nov.2.2017)

EA Pharma, a gastroenterology subsidiary of Eisai, said on October 31 that it has cut a licensing deal with South Korea’s JW Pharmaceutical, granting rights to develop and market its AJT240 for the treatment of secondary hyperparathyroidism in hemodialysis patients in South Korea ...
(LOG IN FOR FULL STORY)

News Calendar